valproic acid has been researched along with Malignant Melanoma in 23 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We explored in a phase I/II clinical trial the combination of valproic acid (VPA), a clinically available histone deacetylase inhibitor, with standard chemoimmunotherapy in patients with advanced melanoma, to evaluate its clinical activity, to correlate the clinical response with the biological activity of VPA and to assess toxicity." | 9.14 | A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. ( Ballarini, M; Contegno, F; Croci, D; Goldhirsch, A; Minucci, S; Munzone, E; Nolè, F; Pelicci, PG; Rocca, A; Salmaggi, A; Testori, A; Tosti, G, 2009) |
| " A phase I/II trial of valproic acid (VPA) and KTN was conducted in patients with stage IV melanoma, with any number of prior therapies, Eastern Cooperative Oncology Group performance status 0-2, and adequate organ function." | 9.14 | Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. ( Bastien, S; Bicaku, E; Daud, AI; Dawson, J; DeConti, RC; Hausheer, FA; Lush, R; Marchion, D; Munster, PN; Neuger, A; Sullivan, DM, 2009) |
| " In this study, we found that the use of VPA in combination with talazoparib (BMN-673-PARP1 inhibitor-PARPi) and/or Dacarbazine (DTIC-alkylating agent) resulted in an increased rate of DNA double strand breaks (DSBs) and reduced survival (while not affecting primary melanocytes) and the proliferation of melanoma cells." | 8.31 | Histone Deacetylases (HDAC) Inhibitor-Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor. ( Barszczewska-Pietraszek, G; Czarny, P; Czyż, M; Drzewiecka, M; Gajos-Michniewicz, A; Hoser, G; Jaśniak, D; Piekarski, J; Radek, M; Sitarek, P; Skorski, T; Śliwiński, T, 2023) |
| "Histone deacetylase inhibitors, including valproic acid, selectively induce cellular differentiation and apoptosis in melanoma cells." | 7.96 | Association of Valproic Acid Use, a Potent Histone Deacetylase Inhibitor, and Melanoma Risk. ( Asgari, MM; Chavez, A; Darbinian, J; Quesenberry, CP, 2020) |
| "Cucurbitacin B (CuB) is reported to have anti-proliferation effects on a variety of tumors including melanoma, and more effective regimens by combination of this agent with others are under investigation." | 7.77 | Histone deacetylase inhibitor valproic acid sensitizes B16F10 melanoma cells to cucurbitacin B treatment. ( He, X; Li, J; Ouyang, D; Xu, L; Zha, Q; Zhang, Y, 2011) |
| "Melanoma is the most lethal form of skin cancer, which is intrinsically resistant to conventional chemotherapy." | 5.62 | Synergistic Effect of Simultaneous versus Sequential Combined Treatment of Histone Deacetylase Inhibitor Valproic Acid with Etoposide on Melanoma Cells. ( Chuang, YJ; Liu, LY; Shyu, YM, 2021) |
| "We explored in a phase I/II clinical trial the combination of valproic acid (VPA), a clinically available histone deacetylase inhibitor, with standard chemoimmunotherapy in patients with advanced melanoma, to evaluate its clinical activity, to correlate the clinical response with the biological activity of VPA and to assess toxicity." | 5.14 | A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. ( Ballarini, M; Contegno, F; Croci, D; Goldhirsch, A; Minucci, S; Munzone, E; Nolè, F; Pelicci, PG; Rocca, A; Salmaggi, A; Testori, A; Tosti, G, 2009) |
| " A phase I/II trial of valproic acid (VPA) and KTN was conducted in patients with stage IV melanoma, with any number of prior therapies, Eastern Cooperative Oncology Group performance status 0-2, and adequate organ function." | 5.14 | Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. ( Bastien, S; Bicaku, E; Daud, AI; Dawson, J; DeConti, RC; Hausheer, FA; Lush, R; Marchion, D; Munster, PN; Neuger, A; Sullivan, DM, 2009) |
| " In this study, we found that the use of VPA in combination with talazoparib (BMN-673-PARP1 inhibitor-PARPi) and/or Dacarbazine (DTIC-alkylating agent) resulted in an increased rate of DNA double strand breaks (DSBs) and reduced survival (while not affecting primary melanocytes) and the proliferation of melanoma cells." | 4.31 | Histone Deacetylases (HDAC) Inhibitor-Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor. ( Barszczewska-Pietraszek, G; Czarny, P; Czyż, M; Drzewiecka, M; Gajos-Michniewicz, A; Hoser, G; Jaśniak, D; Piekarski, J; Radek, M; Sitarek, P; Skorski, T; Śliwiński, T, 2023) |
| "Histone deacetylase inhibitors, including valproic acid, selectively induce cellular differentiation and apoptosis in melanoma cells." | 3.96 | Association of Valproic Acid Use, a Potent Histone Deacetylase Inhibitor, and Melanoma Risk. ( Asgari, MM; Chavez, A; Darbinian, J; Quesenberry, CP, 2020) |
| "Matrigel and Collagen invasion assays were performed to evaluate the effect of several HDACi (Butyrate, Trichostatin A, Valproic acid and Vorinostat) on two human melanoma cell line invasion (A375 and HT-144)." | 3.83 | Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity. ( Andrade, R; Aréchaga, J; Arluzea, J; De Wever, O; Díaz-Núñez, M; Díez-Torre, A; Silió, M, 2016) |
| "Cucurbitacin B (CuB) is reported to have anti-proliferation effects on a variety of tumors including melanoma, and more effective regimens by combination of this agent with others are under investigation." | 3.77 | Histone deacetylase inhibitor valproic acid sensitizes B16F10 melanoma cells to cucurbitacin B treatment. ( He, X; Li, J; Ouyang, D; Xu, L; Zha, Q; Zhang, Y, 2011) |
| "Melanoma is the most lethal form of skin cancer, which is intrinsically resistant to conventional chemotherapy." | 1.62 | Synergistic Effect of Simultaneous versus Sequential Combined Treatment of Histone Deacetylase Inhibitor Valproic Acid with Etoposide on Melanoma Cells. ( Chuang, YJ; Liu, LY; Shyu, YM, 2021) |
| " We conclude that targeting MC2 Ag, combined with epigenetic drug-enhanced antigenicity, allows for significant and tumor-selective T cell responses." | 1.43 | MAGE-C2-Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell Responses. ( Coulie, PG; da Silva, M; Debets, R; Kunert, A; Lamers, C; Sleijfer, S; van Brakel, M; van Steenbergen-Langeveld, S, 2016) |
| "To investigate their potential use as cancer testis antigen (CTA) vaccines, we studied the expression of 12 cancer testis (CT) genes in 20 LCL by RT-PCR." | 1.39 | EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors. ( Held, G; Kaddu-Mulindwa, D; Kubuschok, B; Neumann, F; Pfreundschuh, M; Preuss, KD; Roemer, K; Widmann, T; Zwick, C, 2013) |
| "Valproic acid (VPA) is an established drug in the long-term therapy of epilepsy." | 1.36 | Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells. ( Ferreri, AM; Guerra, F; Orlandi, M; Papi, A; Rocchi, P, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (30.43) | 29.6817 |
| 2010's | 9 (39.13) | 24.3611 |
| 2020's | 7 (30.43) | 2.80 |
| Authors | Studies |
|---|---|
| Barbaraci, C | 1 |
| Giurdanella, G | 1 |
| Leotta, CG | 1 |
| Longo, A | 1 |
| Amata, E | 1 |
| Dichiara, M | 1 |
| Pasquinucci, L | 1 |
| Turnaturi, R | 1 |
| Prezzavento, O | 1 |
| Cacciatore, I | 1 |
| Zuccarello, E | 1 |
| Lupo, G | 1 |
| Pitari, GM | 1 |
| Anfuso, CD | 1 |
| Marrazzo, A | 1 |
| Shyu, YM | 1 |
| Liu, LY | 1 |
| Chuang, YJ | 2 |
| Li, S | 1 |
| Wang, Y | 1 |
| Yan, H | 1 |
| Lai, ZY | 1 |
| Li, DY | 1 |
| Huang, CY | 1 |
| Tung, KC | 1 |
| Yang, CC | 1 |
| Liu, HM | 1 |
| Chou, FI | 1 |
| Drzewiecka, M | 1 |
| Gajos-Michniewicz, A | 1 |
| Hoser, G | 1 |
| Jaśniak, D | 1 |
| Barszczewska-Pietraszek, G | 1 |
| Sitarek, P | 1 |
| Czarny, P | 1 |
| Piekarski, J | 1 |
| Radek, M | 1 |
| Czyż, M | 1 |
| Skorski, T | 1 |
| Śliwiński, T | 1 |
| Chavez, A | 1 |
| Quesenberry, CP | 1 |
| Darbinian, J | 1 |
| Asgari, MM | 1 |
| Saakyan, SV | 1 |
| Tsygankov, АY | 1 |
| Moiseeva, NI | 1 |
| Karamysheva, АF | 1 |
| Garri, DD | 1 |
| Jennings, VA | 1 |
| Scott, GB | 1 |
| Rose, AMS | 1 |
| Scott, KJ | 1 |
| Migneco, G | 1 |
| Keller, B | 1 |
| Reilly, K | 1 |
| Donnelly, O | 1 |
| Peach, H | 1 |
| Dewar, D | 1 |
| Harrington, KJ | 1 |
| Pandha, H | 1 |
| Samson, A | 1 |
| Vile, RG | 1 |
| Melcher, AA | 1 |
| Errington-Mais, F | 1 |
| Neumann, F | 1 |
| Kaddu-Mulindwa, D | 1 |
| Widmann, T | 1 |
| Preuss, KD | 1 |
| Held, G | 1 |
| Zwick, C | 1 |
| Roemer, K | 1 |
| Pfreundschuh, M | 1 |
| Kubuschok, B | 1 |
| Kunert, A | 1 |
| van Brakel, M | 1 |
| van Steenbergen-Langeveld, S | 1 |
| da Silva, M | 1 |
| Coulie, PG | 1 |
| Lamers, C | 1 |
| Sleijfer, S | 1 |
| Debets, R | 1 |
| Díaz-Núñez, M | 1 |
| Díez-Torre, A | 1 |
| De Wever, O | 1 |
| Andrade, R | 1 |
| Arluzea, J | 1 |
| Silió, M | 1 |
| Aréchaga, J | 1 |
| Otsuki, A | 1 |
| Patel, A | 1 |
| Kasai, K | 1 |
| Suzuki, M | 1 |
| Kurozumi, K | 1 |
| Chiocca, EA | 1 |
| Saeki, Y | 1 |
| Rocca, A | 1 |
| Minucci, S | 2 |
| Tosti, G | 1 |
| Croci, D | 1 |
| Contegno, F | 1 |
| Ballarini, M | 2 |
| Nolè, F | 1 |
| Munzone, E | 1 |
| Salmaggi, A | 1 |
| Goldhirsch, A | 1 |
| Pelicci, PG | 1 |
| Testori, A | 1 |
| Daud, AI | 1 |
| Dawson, J | 1 |
| DeConti, RC | 1 |
| Bicaku, E | 1 |
| Marchion, D | 1 |
| Bastien, S | 1 |
| Hausheer, FA | 1 |
| Lush, R | 1 |
| Neuger, A | 1 |
| Sullivan, DM | 1 |
| Munster, PN | 1 |
| Papi, A | 1 |
| Ferreri, AM | 1 |
| Rocchi, P | 1 |
| Guerra, F | 1 |
| Orlandi, M | 1 |
| Roos, WP | 1 |
| Jöst, E | 1 |
| Belohlavek, C | 1 |
| Nagel, G | 1 |
| Fritz, G | 1 |
| Kaina, B | 1 |
| Ouyang, D | 1 |
| Zhang, Y | 1 |
| Xu, L | 1 |
| Li, J | 1 |
| Zha, Q | 1 |
| He, X | 1 |
| Landreville, S | 1 |
| Agapova, OA | 1 |
| Matatall, KA | 1 |
| Kneass, ZT | 1 |
| Onken, MD | 1 |
| Lee, RS | 1 |
| Bowcock, AM | 1 |
| Harbour, JW | 1 |
| Chodurek, E | 1 |
| Orchel, A | 1 |
| Orchel, J | 1 |
| Kurkiewicz, S | 1 |
| Gawlik, N | 1 |
| Dzierżewicz, Z | 1 |
| Stępień, K | 1 |
| Facchetti, F | 1 |
| Previdi, S | 1 |
| Perego, P | 1 |
| La Porta, CA | 1 |
| Valentini, A | 1 |
| Gravina, P | 1 |
| Federici, G | 1 |
| Bernardini, S | 1 |
| Krämer, OH | 1 |
| Knauer, SK | 1 |
| Zimmermann, D | 1 |
| Stauber, RH | 1 |
| Heinzel, T | 1 |
| Khan, AN | 1 |
| Gregorie, CJ | 1 |
| Tomasi, TB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adoptive Therapy With TCR Gene-engineered T Cells to Treat Patients With MAGE-C2-positive Melanoma and Head and Neck Cancer[NCT04729543] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2020-10-20 | Recruiting | ||
| PLA General Hospital[NCT05920512] | Phase 1/Phase 2 | 10 participants (Anticipated) | Interventional | 2022-04-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for valproic acid and Malignant Melanoma
| Article | Year |
|---|---|
A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma.
Topics: Adult; Aged; Dacarbazine; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Humans; Interfe | 2009 |
Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2009 |
21 other studies available for valproic acid and Malignant Melanoma
| Article | Year |
|---|---|
Haloperidol Metabolite II Valproate Ester (
Topics: Angiogenesis Inhibitors; Butyrophenones; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans | 2021 |
Synergistic Effect of Simultaneous versus Sequential Combined Treatment of Histone Deacetylase Inhibitor Valproic Acid with Etoposide on Melanoma Cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Synergism; Etoposide; G2 Phase Cell Cycle | 2021 |
[Valproate up-regulates the expression of NKG2DL through the MEK/ERK signaling pathway to enhance the killing effect of NK cells on A375 human melanoma cells].
Topics: Animals; Cell Line, Tumor; Histocompatibility Antigens Class I; Homicide; Humans; Killer Cells, Natu | 2022 |
Valproic Acid Enhances Radiosensitization
Topics: Animals; DNA; DNA Breaks, Double-Stranded; Humans; Melanoma; Mice; Neoplasm Recurrence, Local; Neutr | 2022 |
Histone Deacetylases (HDAC) Inhibitor-Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor.
Topics: Alkylating Agents; Antineoplastic Agents; Dacarbazine; DNA; Histone Deacetylase Inhibitors; Histone | 2023 |
Association of Valproic Acid Use, a Potent Histone Deacetylase Inhibitor, and Melanoma Risk.
Topics: Adult; Aged; Disease Progression; Female; Follow-Up Studies; Histone Deacetylase Inhibitors; Humans; | 2020 |
Assessment of the Chemosensitivity of Uveal Melanoma Cells Ex Vivo.
Topics: Adult; Aged; Antineoplastic Agents; Benzeneacetamides; Busulfan; Cell Proliferation; Cell Survival; | 2020 |
Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.
Topics: Antigens, Neoplasm; Antineoplastic Agents, Immunological; Biological Products; Cell Survival; Dendri | 2019 |
EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors.
Topics: Antigen-Presenting Cells; Antigens, Neoplasm; Azacitidine; B-Lymphocytes; Cancer Vaccines; CD4-Posit | 2013 |
MAGE-C2-Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell Responses.
Topics: Antigens, Neoplasm; Azacitidine; B7-1 Antigen; B7-2 Antigen; B7-H1 Antigen; Cell Line, Tumor; Epitop | 2016 |
Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity.
Topics: Antineoplastic Agents; Apoptosis; Butyrates; Cadherins; Cell Line, Tumor; Gene Expression Regulation | 2016 |
Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Butyrates; Drug Synergism; Drug Therapy, Combinatio | 2008 |
Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells.
Topics: Anticonvulsants; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation | 2010 |
Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN-β and valproic acid.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 8; Cell Line, Tumor; Dacarbazine; DNA Breaks, Dou | 2011 |
Histone deacetylase inhibitor valproic acid sensitizes B16F10 melanoma cells to cucurbitacin B treatment.
Topics: Animals; Apoptosis; Autophagy; Cell Line, Tumor; Chloroquine; Drug Synergism; Histone Deacetylase In | 2011 |
Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.
Topics: Animals; Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Chemorad | 2012 |
Evaluation of melanogenesis in A-375 melanoma cells treated with 5,7-dimethoxycoumarin and valproic acid.
Topics: Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Coumarins; Gas Chromatography-Mass Spect | 2012 |
Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; DNA Primers; Drug Resistance, Neoplasm; | 2004 |
Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Etoposide; Genes, p16; Humans; Melano | 2007 |
Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis.
Topics: Apoptosis; Caspase 3; Caspase Inhibitors; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhi | 2008 |
Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells.
Topics: Animals; Antigen Presentation; ATP Binding Cassette Transporter, Subfamily B, Member 2; ATP Binding | 2008 |